Clinical Disclaimer

This paper describes a proposed measurement instrument and its proposed validation program. It has not been built or clinically validated, is not FDA approved, and nothing in this paper constitutes medical advice or a diagnostic claim. The validation studies described in Part IV have not yet been conducted.

Abstract

This paper specifies the engineering-level implementation of the Coherence Quantification Index (CQI), a proposed composite measurement instrument built on five real, independently established biometric measurement domains, heart rate variability, EEG phase relationships, bioimpedance spectroscopy, biophoton detection, and SQUID magnetometry, combined into a single composite score via a proposed weighted equation.

The paper's own "Response to Critics" section makes an unusually clean and correct methodological move: it explicitly separates the measurement instrument, which depends only on established physics and physiology, from this framework's deeper speculative theoretical claims (toroidal time, vacuum information storage, and others), stating that the CQI measurement architecture stands or falls on its own falsifiable predictions regardless of whether the deeper theory is ever confirmed. This page preserves that separation prominently. The complete hardware, firmware, and weighting specifications are not disclosed in this public version; the full validation program and its fifteen falsifiable predictions are published here in full.

I. What the CQI Measures

The paper proposes the CQI as a composite scalar (0 to 1) combining five independently measured biometric domains into a single score, on the premise that phase alignment and low-entropy organization across multiple physiological systems reflects a single underlying "coherence" state. Each of the five underlying measurement domains draws on real, independently established science: heart rate variability is a genuinely extensive, decades-old research area; EEG phase-locking analysis is a real, standard neuroscience technique; bioimpedance spectroscopy and SQUID magnetometry are both real, established biomedical measurement methods; and biophoton emission from living tissue is a real, documented phenomenon with a genuinely substantial published research history. The claim that combining these five measurements into a single weighted composite score captures one unified "coherence" state is this paper's own hypothesis, not an established finding, and is precisely what the validation program in Part IV is designed to test.

II. The Five Measurement Domains

The paper proposes specific instrumentation for each domain: an HRV sensor patch, an eight-channel EEG array, a composite sensor integrating bioimpedance and biophoton detection with SQUID magnetometry, an acoustic response profiling system, and a separate electromagnetic array. Each domain's real underlying measurement technique is genuine and independently used in legitimate biomedical research and, in several cases, clinical practice; the specific proposed integration weight assigned to each domain in the composite score, and the specific proposed acoustic-response coherence measure, are this paper's own construct. The complete composite equation's weighting coefficients are not disclosed in this public version.

III. Hardware and Firmware

The paper proposes a complete, manufacturer-ready specification: component-level bills of materials for every sensor, firmware written in C, and detailed calibration and quality-assurance procedures, including a proposed adaptive calibration protocol that adjusts an individual user's baseline over a 30-day period rather than relying solely on a fixed population reference. The complete hardware bills of materials, firmware source code, and calibration threshold values are not disclosed in this public version, consistent with the standing policy applied to source code and device specifications throughout this library.

IV. Validation Architecture

The paper proposes five validation studies with specific sample sizes, designs, and pre-specified statistical success criteria, published here in full, along with the complete summary of all fifteen individual falsifiable predictions the paper proposes across its five measurement domains.

Study	Design	Primary Hypothesis	Success Criterion
CQI-V1 (Inter-Rater)	N=100, two operators, measurements one hour apart	Two independent operators measuring the same subject agree	r > 0.90; p < 0.001
CQI-V2 (Test-Retest)	N=100, same operator, measurements one week apart	Repeated measurement of the same subject is consistent over time	r > 0.85; p < 0.001
CQI-V3 (Convergent Validity)	N=1,000, baseline and five-year follow-up	CQI correlates with established clinical biomarkers (HRV RMSSD, EEG gamma, CRP, mortality)	r > 0.70 per biomarker; p < 0.001
CQI-V4 (Responsiveness)	N=100, eight-week coherence training protocol, pre/post	CQI changes meaningfully in response to a training intervention	ΔCQI ≥ 0.15; p < 0.01
CQI-V5 (Cross-Cultural)	N=100 across five cultural backgrounds	CQI measurement is not culturally biased	r > 0.85 across all groups; p < 0.001

The paper's own stated research budget for this five-study program is roughly $2,075,000. All fifteen individual predictions, three per domain (a correlation prediction, an outcome prediction, and a training-responsiveness prediction), are published here with their falsification thresholds:

Prediction	Statement	Falsification Threshold
P-HRV-1	C_HRV correlates with RMSSD, r > 0.85, N=100	r < 0.70
P-HRV-2	C_HRV > 0.75 predicts reduced 5-year all-cause mortality, HR < 0.70	HR > 0.85
P-HRV-3	Coherence training increases C_HRV by ≥ 0.15 over 8 weeks	Δ < 0.10
P-EEG-1	C_EEG correlates with gamma PLV, r > 0.80, N=100	r < 0.65
P-EEG-2	C_EEG > 0.75 predicts cognitive improvement ≥ 1 SD	< 0.5 SD
P-EEG-3	Coherence training increases C_EEG by ≥ 0.10 over 8 weeks	Δ < 0.06
P-C0-1	C_C0 correlates with HRV and EEG coherence, r > 0.70, N=100	r < 0.55
P-C0-2	C_C0 > 0.75 predicts CRP < 1.0 mg/L over 12 months	CRP > 2.0 mg/L
P-C0-3	Coherence training increases C_C0 by ≥ 0.15 over 8 weeks	Δ < 0.10
P-AC-1	C_Acoustic correlates with HRV and EEG, r > 0.65, N=100	r < 0.50
P-AC-2	C_Acoustic > 0.75 predicts pain reduction ≥ 30% on VAS	< 15%
P-AC-3	Coherence training increases C_Acoustic by ≥ 0.10 over 8 weeks	Δ < 0.06
P-EM-1	C_EM correlates with HRV and EEG, r > 0.70, N=100	r < 0.55
P-EM-2	C_EM > 0.75 predicts reduced 5-year all-cause mortality, HR < 0.70	HR > 0.85
P-EM-3	Coherence training increases C_EM by ≥ 0.15 over 8 weeks	Δ < 0.10

V. Response to Critics

This section is the paper's own response to four objections, and this page preserves it closely because it represents a genuinely correct and disciplined way to handle the relationship between a measurement instrument and a broader speculative theory. Addressing the objection that "toroidal time has no experimental confirmation," the paper states directly: "The CQI measurement architecture does not require toroidal time to be established as physical fact. It requires only that coherence is a measurable physical property… If these hypotheses are confirmed, the CQI measurement framework is validated regardless of whether the deeper toroidal physics is confirmed."

Addressing the objection that nothing in quantum field theory supports vacuum information storage, the paper is equally direct: the bioelectric and biophoton measurements detect "actual photon emission from living tissue, a well-established phenomenon with a 60-year research literature," and "actual magnetic fields generated by cardiac and neural activity," neither of which requires the vacuum to store information; the paper states plainly that its Akashic Ledger concept "is a separate architectural layer… and is not part of this measurement specification." Addressing the objection that no established physics links HRV to crystal lattice behavior, the paper states that its proposed Heart-Lock network mechanism "is a system design requirement for the CQI network layer, not a measurement claim," and that the measurement framework "is valid regardless of whether the Heart-Lock coupling is subsequently confirmed." Addressing the objection that no physics can forecast individual future events, the paper is explicit that the CQI "does not forecast individual future events," and that its claims are limited to measuring current state, comparing it to a baseline, tracking change over time, and testing correlation with outcomes, "all of which are falsifiable."

This page adopts the same standard throughout this document: the measurement instrument described in Parts I through IV rests on real, established science, and its validity does not depend on whether this framework's more speculative claims, discussed and hedged elsewhere throughout this library, are ever confirmed.

VI. Manufacturer Handoff

The paper proposes a complete manufacturer handoff package including device certification pathway guidance and quality assurance procedures. Consistent with this document's own confidentiality framing and the standing policy applied throughout this library, the complete handoff package is not disclosed in this public version.

Intellectual Property & Disclosure Statement

The CQI measurement architecture, its five-domain composite scoring system, and its proposed hardware and firmware are original work of Joshua Farrior, claimed as intellectual property of Joshua Farrior / Christos™ Energy, Technology & Harmonic Design Consulting, LLC.

Withheld in full: the composite equation's exact weighting coefficients; the complete hardware bills of materials and firmware source code for all five measurement domains; the adaptive calibration protocol's specific parameters; and the complete manufacturer handoff package. None of this has been built or clinically validated. Nothing in this paper constitutes medical advice or a diagnostic claim.

© 2026 Joshua Farrior · Christos™ Energy, Technology & Harmonic Design Consulting, LLC · All Rights Reserved · Business ID: 202511071941923 · Christos™ trademark pending USPTO review · Not FDA approved · christosenergy.com